TY - JOUR
T1 - Adjuvant Therapy for Node-Positive Colon Cancer
AU - Shirazi, Haider A.
AU - Singhvi, Mamta
AU - Small, William
AU - Benson, Al B.
PY - 2008/12
Y1 - 2008/12
N2 - The adjuvant therapy for node positive colon cancer (stage III) reflects an evolutionary process incorporating strategies based on risk assessment and expansion of therapeutic options. Risk assessment is currently determined by pathologic features including grade of tumor, T-stage and nodal status, as well as number of lymph nodes reported. There is a growing interest in the utilization of molecular markers as a risk stratification strategy. Such, current randomized colon clinical trials include the collection of tumor specimens for molecular assessment and multivariate analyses of prognostic and predictive factors. Most recent clinical trials have established the efficacy of oxaliplatin, 5-FU and leucovorin as the standard of care for stage III colon cancer patients. In addition, the monoclonal antibodies, bevacizumab and cetuximab, have been integrated into recent randomized clinical trial designs, based on efficacy data from advanced disease trials.
AB - The adjuvant therapy for node positive colon cancer (stage III) reflects an evolutionary process incorporating strategies based on risk assessment and expansion of therapeutic options. Risk assessment is currently determined by pathologic features including grade of tumor, T-stage and nodal status, as well as number of lymph nodes reported. There is a growing interest in the utilization of molecular markers as a risk stratification strategy. Such, current randomized colon clinical trials include the collection of tumor specimens for molecular assessment and multivariate analyses of prognostic and predictive factors. Most recent clinical trials have established the efficacy of oxaliplatin, 5-FU and leucovorin as the standard of care for stage III colon cancer patients. In addition, the monoclonal antibodies, bevacizumab and cetuximab, have been integrated into recent randomized clinical trial designs, based on efficacy data from advanced disease trials.
UR - http://www.scopus.com/inward/record.url?scp=56649086667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649086667&partnerID=8YFLogxK
U2 - 10.1053/j.scrs.2008.09.005
DO - 10.1053/j.scrs.2008.09.005
M3 - Article
AN - SCOPUS:56649086667
SN - 1043-1489
VL - 19
SP - 191
EP - 196
JO - Seminars in Colon and Rectal Surgery
JF - Seminars in Colon and Rectal Surgery
IS - 4
ER -